ADAGENE INC

Adagene insider buying sparks optimism: director DO CUONG V’s recent ADS purchase signals confidence in the company’s antibody platform and dual‑market strategy amid a volatile biotech sector.

Adagene insiders boost shares at $3.00, signaling confidence in its cancer‑drug pipeline and potential undervaluation.

Adagene’s insider buying signals confidence as new clinical milestones loom, hinting at a potential rebound in a volatile share price.

Adagene insider activity: Gu Chunfang’s holdings reveal confidence in the antibody pipeline and potential upside for investors.

Adagene insider moves show senior execs stay long‑term invested, aligning options with milestone wins and reducing dilution risk for investors.